Old Web
English
Sign In
Acemap
>
authorDetail
>
Chris Rovaldi
Chris Rovaldi
Myelodysplastic syndromes
Medicine
Internal medicine
Lower risk
Oncology
3
Papers
0
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
A Phase 2, Open-Label, Ascending Dose Study of Ker-050 for the Treatment of Anemia in Patients with Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes
2021
Blood
David M. Ross
Alejandro Arbelaez
Lynette C.Y. Chee
Chun Yew Fong
Devendra K. Hiwase
George Kannourakis
John Kwan
James Liang
Anish Puliyayil
Hannah Rose
Shuhying Tan
Tse-Chieh Teh
David Westerman
Joel Wight
Chris Rovaldi
Elissa Furutani
Adrienne Gaggi
Ying Jiang
Jenn Lachey
Harveen Dhillon Natarajan
Claudia Ordonez
Show All
Source
Cite
Save
Citations (0)
Erythropoietic cellular analyses in luspatercept-treated lower-risk myelodysplastic syndromes (MDS): Phase 2 PACE-MDS study.
2018
Journal of Clinical Oncology
Uwe Platzbecker
Aristoteles Giagounidis
Philipp Kiewe
Ulrich Germing
Katharina Götze
Karin Mayer
Markus P. Radsak
Thomas Wolff
Jörg Chromik
Joseph G. Reynolds
Carolyn Barron
Chris Rovaldi
Rajasekhar Nvs Suragani
Xiaosha Zhang
Abderrahmane Laadem
Peter G. Linde
Matthew L. Sherman
Uta Oelschlägel
Show All
Source
Cite
Save
Citations (0)
Mutational Profile and Analysis of Lower-Risk Myelodysplastic Syndromes (MDS) Patients Treated with Luspatercept: Phase 2 PACE-MDS Study
2017
Blood
Uwe Platzbecker
Philipp Kiewe
Ulrich Germing
Katharina Götze
Karin Mayer
Markus P. Radsak
Thomas Wolff
Joerg Chromik
Dawn Wilson
Xiaosha Zhang
Chris Rovaldi
Abderrahmane Laadem
Matthew L. Sherman
Kenneth M. Attie
Joseph G. Reynolds
Peter G. Linde
Aristoteles Giagounidis
Show All
Source
Cite
Save
Citations (0)
1